The clinical implications of antitumor immunity in head and neck cancer

Laryngoscope

Volumn 122, Issue 1, 2012, Pages 144-157

  Allen, Clint T ^a   Judd, Nancy P ^a   Bui, Jack D ^b   Uppaluri, Ravindra ^a  

^a WASHINGTON UNIVERSITY   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

head and neck cancer; immunotherapy; standard therapy; Tumor immunity

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; CETUXIMAB; CISPLATIN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 12; INTERLEUKIN 2; IRX 2; UNCLASSIFIED DRUG;

ADAPTIVE IMMUNITY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CARCINOGENESIS; HEAD AND NECK CANCER; HUMAN; IMMUNOTHERAPY; INNATE IMMUNITY; LAPAROTOMY; MOUTH CANCER; NONHUMAN; PRIORITY JOURNAL; REVIEW; SQUAMOUS CELL CARCINOMA; TUMOR IMMUNITY;

HEAD AND NECK NEOPLASMS; HUMANS; TUMOR ESCAPE; TUMOR MICROENVIRONMENT;

EID: 84255191129     PISSN: 0023852X     EISSN: 15314995     Source Type: Journal    
DOI: 10.1002/lary.21913     Document Type: Review

References (224)

1. Ang KK, Harris J, Wheeler R, et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 2010; 363: 24-35.
2. Hoption Cann SA, van Netten JP, van Netten C,. Dr William Coley and tumour regression: a place in history or in the future. Postgrad Med J 2003; 79: 672-680. (Pubitemid 38134682)
3. Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD,. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 2002; 3: 991-998. (Pubitemid 35363648)
4. Whiteside TL,. Anti-tumor vaccines in head and neck cancer: targeting immune responses to the tumor. Curr Cancer Drug Targets 2007; 7: 633-642. (Pubitemid 350074966)
5. Molinolo AA, Amornphimoltham P, Squarize CH, Castilho RM, Patel V, Gutkind JS,. Dysregulated molecular networks in head and neck carcinogenesis. Oral Oncol 2009; 45: 324-334.
6. Perez-Ordonez B, Beauchemin M, Jordan RC,. Molecular biology of squamous cell carcinoma of the head and neck. J Clin Pathol 2006; 59: 445-453.
7. Hanahan D, Weinberg RA,. The hallmarks of cancer. Cell 2000; 100: 57-70. (Pubitemid 30046295)
8. Neiva KG, Zhang Z, Miyazawa M, Warner KA, Karl E, Nor JE,. Cross talk initiated by endothelial cells enhances migration and inhibits anoikis of squamous cell carcinoma cells through STAT3/Akt/ERK signaling. Neoplasia 2009; 11: 583-593.
9. Kono H, Rock KL,. How dying cells alert the immune system to danger. Nat Rev Immunol 2008; 8: 279-289. (Pubitemid 351432799)
10. Dunn GP, Old LJ, Schreiber RD,. The three Es of cancer immunoediting. Annu Rev Immunol 2004; 22: 329-360. (Pubitemid 38680426)
11. Street SE, Trapani JA, MacGregor D, Smyth MJ,. Suppression of lymphoma and epithelial malignancies effected by interferon gamma. J Exp Med 2002; 196: 129-134. (Pubitemid 34747318)
12. Shankaran V, Ikeda H, Bruce AT, et al. IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 2001; 410: 1107-1111. (Pubitemid 32391043)
13. Uppaluri R, Dunn GP, Lewis JS Jr,. Focus on TILs: prognostic significance of tumor infiltrating lymphocytes in head and neck cancers. Cancer Immun 2008; 8: 16.
14. Ku TK, Crowe DL,. Impaired T lymphocyte function increases tumorigenicity and decreases tumor latency in a mouse model of head and neck cancer. Int J Oncol 2009; 35: 1211-1221.
15. Dunn GP, Koebel CM, Schreiber RD,. Interferons, immunity and cancer immunoediting. Nat Rev Immunol 2006; 6: 836-848. (Pubitemid 44631652)
16. Schreiber RD, Old LJ, Smyth MJ,. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science 2011; 331: 1565-1570.
17. Birkeland SA, Storm HH, Lamm LU, et al. Cancer risk after renal transplantation in the Nordic countries, 1964-1986. Int J Cancer 1995; 60: 183-189.
18. Pham SM, Kormos RL, Landreneau RJ, et al. Solid tumors after heart transplantation: lethality of lung cancer. Ann Thorac Surg 1995; 60: 1623-1626. (Pubitemid 26079155)
19. Penn I,. Depressed immunity and the development of cancer. Cancer Detect Prev 1994; 18: 241-252. (Pubitemid 2131937)
20. Bhatia S, Louie AD, Bhatia R, et al. Solid cancers after bone marrow transplantation. J Clin Oncol 2001; 19: 464-471. (Pubitemid 32112860)
21. Vajdic CM, McDonald SP, McCredie MR, et al. Cancer incidence before and after kidney transplantation. JAMA 2006; 296: 2823-2831. (Pubitemid 44969182)
22. Grulich AE, van Leeuwen MT, Falster MO, Vajdic CM,. Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. Lancet 2007; 370: 59-67. (Pubitemid 47017468)
23. Le QT, Shi G, Cao H, et al. Galectin-1: a link between tumor hypoxia and tumor immune privilege. J Clin Oncol 2005; 23: 8932-8941. (Pubitemid 46211478)
24. Brandwein-Gensler M, Teixeira MS, Lewis CM, et al. Oral squamous cell carcinoma: histologic risk assessment, but not margin status, is strongly predictive of local disease-free and overall survival. Am J Surg Pathol 2005; 29: 167-178. (Pubitemid 40170634)
25. Wolf GT, Hudson JL, Peterson KA, Miller HL, McClatchey KD,. Lymphocyte subpopulations infiltrating squamous carcinomas of the head and neck: correlations with extent of tumor and prognosis. Otolaryngol Head Neck Surg 1986; 95: 142-152. (Pubitemid 16025387)
26. Snyderman CH, Heo DS, Chen K, Whiteside TL, Johnson JT,. T-cell markers in tumor-infiltrating lymphocytes of head and neck cancer. Head Neck 1989; 11:331-336. (Pubitemid 19183536)
27. Pretscher D, Distel LV, Grabenbauer GG, Wittlinger M, Buettner M, Niedobitek G,. Distribution of immune cells in head and neck cancer: CD8+ T-cells and CD20+ B-cells in metastatic lymph nodes are associated with favourable outcome in patients with oro- and hypopharyngeal carcinoma. BMC Cancer 2009; 9: 292.
28. Bandoh N, Ogino T, Katayama A, et al. HLA class I antigen and transporter associated with antigen processing downregulation in metastatic lesions of head and neck squamous cell carcinoma as a marker of poor prognosis. Oncol Rep 2010; 23: 933-939.
29. Ogino T, Shigyo H, Ishii H, et al. HLA class I antigen down-regulation in primary laryngeal squamous cell carcinoma lesions as a poor prognostic marker. Cancer Res 2006; 66: 9281-9289. (Pubitemid 44521150)
30. Thurlow JK, Pena Murillo CL, Hunter KD, et al. Spectral clustering of microarray data elucidates the roles of microenvironment remodeling and immune responses in survival of head and neck squamous cell carcinoma. J Clin Oncol 2010; 28: 2881-2818.
31. Hanahan D, Weinberg RA,. Hallmarks of cancer: the next generation. Cell 2011; 144: 646-674.
32. Cutler CW, Jotwani R,. Dendritic cells at the oral mucosal interface. J Dent Res 2006; 85: 678-689. (Pubitemid 44297321)
33. Groothuis T, Neefjes J,. The ins and outs of intracellular peptides and antigen presentation by MHC class I molecules. Curr Top Microbiol Immunol 2005; 300: 127-148.
34. Cresswell P, Ackerman AL, Giodini A, Peaper DR, Wearsch PA,. Mechanisms of MHC class I-restricted antigen processing and cross-presentation. Immunol Rev 2005; 207: 145-157. (Pubitemid 41415014)
35. Borrego F,. The first molecular basis of the "missing self": hypothesis. J Immunol 2006; 177: 5759-5760.
36. Biassoni R,. Natural killer cell receptors. Adv Exp Med Biol 2008; 640: 35-52.
37. Chai JG, Vendetti S, Bartok I, et al. Critical role of costimulation in the activation of naive antigen-specific TCR transgenic CD8+ T cells in vitro. J Immunol 1999; 163: 1298-1305. (Pubitemid 29352747)
38. Dubey C, Croft M, Swain SL,. Costimulatory requirements of naive CD4+ T cells. ICAM-1 or B7-1 can costimulate naive CD4 T cell activation but both are required for optimum response. J Immunol 1995; 155: 45-57.
39. Shaykhiev R, Behr J, Bals R,. Microbial patterns signaling via Toll-like receptors 2 and 5 contribute to epithelial repair, growth and survival. PLoS One 2008; 3: e1393.
40. Zhu J, Yamane H, Paul WE,. Differentiation of effector CD4 T cell populations (*). Annu Rev Immunol 2010; 28: 445-489.
41. Hawkins MJ,. Interleukin-2 antitumor and effector cell responses. Semin Oncol 1993; 20 (Suppl 9): 52-59. (Pubitemid 24018755)
42. Trinchieri G, Pflanz S, Kastelein RA,. The IL-12 family of heterodimeric cytokines: new players in the regulation of T cell responses. Immunity 2003; 19: 641-644. (Pubitemid 37490789)
43. Del Vecchio M, Bajetta E, Canova S, et al. Interleukin-12: biological properties and clinical application. Clin Cancer Res 2007; 13: 4677-4685. (Pubitemid 47294773)
44. Colombo MP, Trinchieri G,. Interleukin-12 in anti-tumor immunity and immunotherapy. Cytokine Growth Factor Rev 2002; 13: 155-168. (Pubitemid 34229390)
45. Janssen EM, Lemmens EE, Gour N, et al. Distinct roles of cytolytic effector molecules for antigen-restricted killing by CTL in vivo. Immunol Cell Biol 2010; 88: 761-765.
46. Zhou F,. Molecular mechanisms of IFN-gamma to up-regulate MHC class I antigen processing and presentation. Int Rev Immunol 2009; 28: 239-260.
47. Fietta P, Delsante G,. The effector T helper cell triade. Riv Biol 2009; 102: 61-74.
48. Noben-Trauth N, Hu-Li J, Paul WE,. Conventional, naive CD4+ T cells provide an initial source of IL-4 during Th2 differentiation. J Immunol 2000; 165: 3620-3625. (Pubitemid 32057265)
49. Dunn G, Oliver KM, Loke D, Stafford ND, Greenman J,. Dendritic cells and HNSCC: a potential treatment option? Oncol Rep 2005; 13: 3-10.
50. Kacani L, Wurm M, Schwentner I, Andrle J, Schennach H, Sprinzl GM,. Maturation of dendritic cells in the presence of living, apoptotic and necrotic tumour cells derived from squamous cell carcinoma of head and neck. Oral Oncol 2005; 41: 17-24. (Pubitemid 39647115)
51. Seya T, Shime H, Ebihara T, Oshiumi H, Matsumoto M,. Pattern recognition receptors of innate immunity and their application to tumor immunotherapy. Cancer Sci 2010; 101: 313-320.
52. Sims GP, Rowe DC, Rietdijk ST, Herbst R, Coyle AJ,. HMGB1 and RAGE in inflammation and cancer. Annu Rev Immunol 2010; 28: 367-388.
53. Fallarino F, Gajewski TF,. Cutting edge: differentiation of antitumor CTL in vivo requires host expression of Stat1. J Immunol 1999; 163: 4109-4113. (Pubitemid 29474472)
54. Koebel CM, Vermi W, Swann JB, et al. Adaptive immunity maintains occult cancer in an equilibrium state. Nature 2007; 450: 903-907. (Pubitemid 350231320)
55. Wieder T, Braumuller H, Kneilling M, Pichler B, Rocken M,. T cell-mediated help against tumors. Cell Cycle 2008; 7: 2974-2977.
56. Olver S, Groves P, Buttigieg K, et al. Tumor-derived interleukin-4 reduces tumor clearance and deviates the cytokine and granzyme profile of tumor-induced CD8+ T cells. Cancer Res 2006; 66: 571-580. (Pubitemid 43166066)
57. Knutson KL, Disis ML,. Tumor antigen-specific T helper cells in cancer immunity and immunotherapy. Cancer Immunol Immunother 2005; 54: 721-728. (Pubitemid 40977140)
58. Barker RN, Erwig LP, Hill KS, Devine A, Pearce WP, Rees AJ,. Antigen presentation by macrophages is enhanced by the uptake of necrotic, but not apoptotic, cells. Clin Exp Immunol 2002; 127: 220-225. (Pubitemid 34233926)
59. Qiu F, Maniar A, Quevedo Diaz M, Chapoval AI, Medvedev AE,. Activation of cytokine-producing and antitumor activities of natural killer cells and macrophages by engagement of Toll-like and NOD-like receptors. Innate Immun 2010 {Epub ahead of print].
60. Martinez FO, Sica A, Mantovani A, Locati M,. Macrophage activation and polarization. Front Biosci 2008; 13: 453-461. (Pubitemid 351599757)
61. Mills CD, Kincaid K, Alt JM, Heilman MJ, Hill AM,. M-1/M-2 macrophages and the Th1/Th2 paradigm. J Immunol 2000; 164: 6166-6173. (Pubitemid 30408793)
62. Nathan C,. Neutrophils and immunity: challenges and opportunities. Nat Rev Immunol 2006; 6: 173-182. (Pubitemid 43290987)
63. Fridlender ZG, Sun J, Kim S, et al. Polarization of tumor-associated neutrophil phenotype by TGF-beta: "N1" versus "N2" TAN. Cancer Cell 2009; 16: 183-194.
64. van der Bruggen P, Traversari C, Chomez P, et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 1991; 254: 1643-1647. (Pubitemid 21917508)
65. Petersen TR, Dickgreber N, Hermans IF,. Tumor antigen presentation by dendritic cells. Crit Rev Immunol 2010; 30: 345-386.
66. Li Y, Depontieu FR, Sidney J, et al. Structural basis for the presentation of tumor-associated MHC class II-restricted phosphopeptides to CD4+ T cells. J Mol Biol 2010; 399: 596-603.
67. Mandruzzato S, Brasseur F, Andry G, Boon T, van der Bruggen P,. A CASP-8 mutation recognized by cytolytic T lymphocytes on a human head and neck carcinoma. J Exp Med 1997; 186: 785-793. (Pubitemid 27381543)
68. Kao H, Marto JA, Hoffmann TK, et al. Identification of cyclin B1 as a shared human epithelial tumor-associated antigen recognized by T cells. J Exp Med 2001; 194: 1313-1323. (Pubitemid 33055049)
69. Vaughan HA, St Clair F, Scanlan MJ, et al. The humoral immune response to head and neck cancer antigens as defined by the serological analysis of tumor antigens by recombinant cDNA expression cloning. Cancer Immun 2004; 4: 5.
70. Atanackovic D, Blum I, Cao Y, et al. Expression of cancer-testis antigens as possible targets for antigen-specific immunotherapy in head and neck squamous cell carcinoma. Cancer Biol Ther 2006; 5: 1218-1225. (Pubitemid 44772241)
71. Heubeck B, Wendler O, Bumm K, et al. Tumor-associated antigenic pattern in squamous cell carcinomas of the head and neck-analysed by SEREX. Eur J Cancer 2006 [Epub ahead of print].
72. Visus C, Ito D, Amoscato A, et al. Identification of human aldehyde dehydrogenase 1 family member A1 as a novel CD8+ T-cell-defined tumor antigen in squamous cell carcinoma of the head and neck. Cancer Res 2007; 67: 10538-10545. (Pubitemid 350070830)
73. Sakakura K, Chikamatsu K, Furuya N, Appella E, Whiteside TL, Deleo AB,. Toward the development of multi-epitope p53 cancer vaccines: an in vitro assessment of CD8(+) T cell responses to HLA class I-restricted wild-type sequence p53 peptides. Clin Immunol 2007; 125: 43-51. (Pubitemid 47374535)
74. Ito D, Visus C, Hoffmann TK, et al. Immunological characterization of missense mutations occurring within cytotoxic T cell-defined p53 epitopes in HLA-A*0201+ squamous cell carcinomas of the head and neck. Int J Cancer 2007; 120: 2618-2624. (Pubitemid 46651283)
75. Kienstra MA, Neel HB, Strome SE, Roche P,. Identification of NY-ESO-1, MAGE-1, and MAGE-3 in head and neck squamous cell carcinoma. Head Neck 2003; 25: 457-463. (Pubitemid 36577030)
76. Schmitt A, Barth TF, Beyer E, et al. The tumor antigens RHAMM and G250/CAIX are expressed in head and neck squamous cell carcinomas and elicit specific CD8+ T cell responses. Int J Oncol 2009; 34: 629-639.
77. Rabassa ME, Croce MV, Pereyra A, Segal-Eiras A,. MUC1 expression and anti-MUC1 serum immune response in head and neck squamous cell carcinoma (HNSCC): a multivariate analysis. BMC Cancer 2006; 6: 253.
78. Cuffel C, Rivals JP, Zaugg Y, et al. Pattern and clinical significance of cancer-testis gene expression in head and neck squamous cell carcinoma. Int J Cancer 2010; 128: 2625-2634.
79. Cesson V, Rivals JP, Escher A, et al. MAGE-A3 and MAGE-A4 specific CD4(+) T cells in head and neck cancer patients: detection of naturally acquired responses and identification of new epitopes. Cancer Immunol Immunother 2011; 60: 23-35.
80. Hoffmann TK, Arsov C, Schirlau K, et al. T cells specific for HPV16 E7 epitopes in patients with squamous cell carcinoma of the oropharynx. Int J Cancer 2006; 118: 1984-1991.
81. Albers A, Abe K, Hunt J, et al. Antitumor activity of human papillomavirus type 16 E7-specific T cells against virally infected squamous cell carcinoma of the head and neck. Cancer Res 2005; 65: 11146-11155. (Pubitemid 41713386)
82. Filho PA, Lopez-Albaitero A, Xi L, Gooding W, Godfrey T, Ferris RL,. Quantitative expression and immunogenicity of MAGE-3 and -6 in upper aerodigestive tract cancer. Int J Cancer 2009; 125: 1912-1920.
83. Hoffmann TK, Donnenberg AD, Finkelstein SD, et al. Frequencies of tetramer+ T cells specific for the wild-type sequence p53(264-272) peptide in the circulation of patients with head and neck cancer. Cancer Res 2002; 62: 3521-3529. (Pubitemid 34651403)
84. Andrade Filho PA, Lopez-Albaitero A, Gooding W, Ferris RL,. Novel immunogenic HLA-A*0201-restricted epidermal growth factor receptor-specific T-cell epitope in head and neck cancer patients. J Immunother 2010; 33: 83-91.
85. Kass ES, Greiner JW, Kantor JA, et al. Carcinoembryonic antigen as a target for specific antitumor immunotherapy of head and neck cancer. Cancer Res 2002; 62: 5049-5057. (Pubitemid 34984433)
86. Lalla RV, Boisoneau DS, Spiro JD, Kreutzer DL,. Expression of vascular endothelial growth factor receptors on tumor cells in head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg 2003; 129: 882-888. (Pubitemid 36966435)
87. Kesselring R, Thiel A, Pries R, Trenkle T, Wollenberg B,. Human Th17 cells can be induced through head and neck cancer and have a functional impact on HNSCC development. Br J Cancer 2010; 103: 1245-1254.
88. Ouyang W, Kolls JK, Zheng Y,. The biological functions of T helper 17 cell effector cytokines in inflammation. Immunity 2008; 28: 454-467. (Pubitemid 351471762)
89. Kortylewski M, Xin H, Kujawski M, et al. Regulation of the IL-23 and IL-12 balance by Stat3 signaling in the tumor microenvironment. Cancer Cell 2009; 15: 114-123.
90. Wu S, Rhee KJ, Albesiano E, et al. A human colonic commensal promotes colon tumorigenesis via activation of T helper type 17 T cell responses. Nat Med 2009; 15: 1016-1022.
91. Ji Y, Zhang W,. Th17 cells: positive or negative role in tumor? Cancer Immunol Immunother 2010; 59: 979-987.
92. Schott AK, Pries R, Wollenberg B,. Permanent up-regulation of regulatory T-lymphocytes in patients with head and neck cancer. Int J Mol Med 2010; 26: 67-75.
93. Hwu P,. Treating cancer by targeting the immune system. N Engl J Med 2010; 363: 779-781.
94. Strauss L, Bergmann C, Szczepanski M, Gooding W, Johnson JT, Whiteside TL,. A unique subset of CD4+CD25highFoxp3+ T cells secreting interleukin-10 and transforming growth factor-beta1 mediates suppression in the tumor microenvironment. Clin Cancer Res 2007; 13 (Pt 1): 4345-4354. (Pubitemid 47219698)
95. Strauss L, Bergmann C, Gooding W, Johnson JT, Whiteside TL,. The frequency and suppressor function of CD4+CD25highFoxp3+ T cells in the circulation of patients with squamous cell carcinoma of the head and neck. Clin Cancer Res 2007; 13: 6301-6311. (Pubitemid 350075018)
96. Bergmann C, Strauss L, Zeidler R, Lang S, Whiteside TL,. Expansion of human T regulatory type 1 cells in the microenvironment of cyclooxygenase 2 overexpressing head and neck squamous cell carcinoma. Cancer Res 2007; 67: 8865-8873. (Pubitemid 47437463)
97. Wilke CM, Wu K, Zhao E, Wang G, Zou W,. Prognostic significance of regulatory T cells in tumor. Int J Cancer 2010; 127: 748-758.
98. Holtmeier W, Kabelitz D,. gammadelta T cells link innate and adaptive immune responses. Chem Immunol Allergy 2005; 86: 151-183.
99. Morita CT, Mariuzza RA, Brenner MB,. Antigen recognition by human gamma delta T cells: pattern recognition by the adaptive immune system. Springer Semin Immunopathol 2000; 22: 191-217.
100. Wu Y, Wu W, Wong WM, et al. Human gamma delta T cells: a lymphoid lineage cell capable of professional phagocytosis. J Immunol 2009; 183: 5622-5629.
101. Havran WL, Chien YH, Allison JP,. Recognition of self antigens by skin-derived T cells with invariant gamma delta antigen receptors. Science 1991; 252: 1430-1432. (Pubitemid 21917062)
102. Skold M, Behar SM,. Role of CD1d-restricted NKT cells in microbial immunity. Infect Immun 2003; 71: 5447-5455. (Pubitemid 37205594)
103. Taniguchi M, Tashiro T, Dashtsoodol N, Hongo N, Watarai H,. The specialized iNKT cell system recognizes glycolipid antigens and bridges the innate and acquired immune systems with potential applications for cancer therapy. Int Immunol 2010; 22: 1-6.
104. Moreno M, Molling JW, von Mensdorff-Pouilly S, et al. IFN-gamma-producing human invariant NKT cells promote tumor-associated antigen-specific cytotoxic T cell responses. J Immunol 2008; 181: 2446-2454.
105. Paster BJ, Boches SK, Galvin JL, et al. Bacterial diversity in human subgingival plaque. J Bacteriol 2001; 183: 3770-3783. (Pubitemid 32510445)
106. Niess JH, Brand S, Gu X, et al. CX3CR1-mediated dendritic cell access to the intestinal lumen and bacterial clearance. Science 2005; 307: 254-258. (Pubitemid 40116240)
107. Van Hoogstraten IM, Andersen KE, Von Blomberg BM, et al. Reduced frequency of nickel allergy upon oral nickel contact at an early age. Clin Exp Immunol 1991; 85: 441-445.
108. Cuburu N, Kweon MN, Song JH, et al. Sublingual immunization induces broad-based systemic and mucosal immune responses in mice. Vaccine 2007; 25: 8598-8610. (Pubitemid 350192038)
109. Garbi N, Hammerling GJ, Probst HC, van den Broek M,. Tonic T cell signalling and T cell tolerance as opposite effects of self-recognition on dendritic cells. Curr Opin Immunol 2010; 22: 601-608.
110. Ferris RL, Whiteside TL, Ferrone S,. Immune escape associated with functional defects in antigen-processing machinery in head and neck cancer. Clin Cancer Res 2006; 12: 3890-3895. (Pubitemid 44078071)
111. Wollenberg B, Zeidler R, Lebeau A, Mack B, Lang S,. Lack of B7.1 and B7.2 on head and neck cancer cells and possible significance for gene therapy. Int J Mol Med 1998; 2: 167-171.
112. Lang S, Whiteside TL, Lebeau A, Zeidler R, Mack B, Wollenberg B,. Impairment of T-cell activation in head and neck cancer in situ and in vitro: strategies for an immune restoration. Arch Otolaryngol Head Neck Surg 1999; 125: 82-88. (Pubitemid 29074903)
113. Thomas GR, Chen Z, Leukinova E, Van Waes C, Wen J,. Cytokines IL-1 alpha, IL-6, and GM-CSF constitutively secreted by oral squamous carcinoma induce down-regulation of CD80 costimulatory molecule expression: restoration by interferon gamma. Cancer Immunol Immunother 2004; 53: 33-40. (Pubitemid 38161179)
114. Couch ME, Ferris RL, Brennan JA, et al. Alteration of cellular and humoral immunity by mutant p53 protein and processed mutant peptide in head and neck cancer. Clin Cancer Res 2007; 13: 7199-7206. (Pubitemid 350276907)
115. Gastman BR, Atarshi Y, Reichert TE, et al. Fas ligand is expressed on human squamous cell carcinomas of the head and neck, and it promotes apoptosis of T lymphocytes. Cancer Res 1999; 59: 5356-5364. (Pubitemid 29504005)
116. Strome SE, Dong H, Tamura H, et al. B7-H1 blockade augments adoptive T-cell immunotherapy for squamous cell carcinoma. Cancer Res 2003; 63: 6501-6505. (Pubitemid 37255203)
117. Saussez S, Camby I, Toubeau G, Kiss R,. Galectins as modulators of tumor progression in head and neck squamous cell carcinomas. Head Neck 2007; 29: 874-884. (Pubitemid 350303676)
118. Dong H, Strome SE, Salomao DR, et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med 2002; 8: 793-800.
119. Brocks CP, Pries R, Frenzel H, Ernst M, Schlenke P, Wollenberg B,. Functional alteration of myeloid dendritic cells through head and neck cancer. Anticancer Res 2007; 27: 817-824. (Pubitemid 46586986)
120. Gabrilovich DI, Chen HL, Girgis KR, et al. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat Med 1996; 2: 1096-1103. (Pubitemid 26338628)
121. Young MR,. Protective mechanisms of head and neck squamous cell carcinomas from immune assault. Head Neck 2006; 28: 462-470. (Pubitemid 43673082)
122. Kacani L, Wurm M, Schennach H, Braun I, Andrle J, Sprinzl GM,. Immunosuppressive effects of soluble factors secreted by head and neck squamous cell carcinoma on dendritic cells and T lymphocytes. Oral Oncol 2003; 39: 672-679. (Pubitemid 36930114)
123. Bailet JW, Lichtenstein A, Chen G, Mickel RA,. Inhibition of lymphocyte function by head and neck carcinoma cell line soluble factors. Arch Otolaryngol Head Neck Surg 1997; 123: 855-862. (Pubitemid 27338030)
124. Gutschalk CM, Herold-Mende CC, Fusenig NE, Mueller MM,. Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor promote malignant growth of cells from head and neck squamous cell carcinomas in vivo. Cancer Res 2006; 66: 8026-8036. (Pubitemid 44299167)
125. Bose A, Chakraborty T, Chakraborty K, Pal S, Baral R,. Dysregulation in immune functions is reflected in tumor cell cytotoxicity by peripheral blood mononuclear cells from head and neck squamous cell carcinoma patients. Cancer Immun 2008; 8: 10.
126. Kuss I, Hathaway B, Ferris RL, Gooding W, Whiteside TL,. Decreased absolute counts of T lymphocyte subsets and their relation to disease in squamous cell carcinoma of the head and neck. Clin Cancer Res 2004; 10: 3755-3762. (Pubitemid 38697609)
127. Molling JW, Langius JA, Langendijk JA, et al. Low levels of circulating invariant natural killer T cells predict poor clinical outcome in patients with head and neck squamous cell carcinoma. J Clin Oncol 2007; 25: 862-868. (Pubitemid 350002887)
128. Albers AE, Schaefer C, Visus C, Gooding W, DeLeo AB, Whiteside TL,. Spontaneous apoptosis of tumor-specific tetramer+ CD8+ T lymphocytes in the peripheral circulation of patients with head and neck cancer. Head Neck 2009; 31: 773-781.
129. Jebreel A, Mistry D, Loke D, et al. Investigation of interleukin 10, 12 and 18 levels in patients with head and neck cancer. J Laryngol Otol 2007; 121: 246-252. (Pubitemid 46833125)
130. Sparano A, Lathers DM, Achille N, Petruzzelli GJ, Young MR,. Modulation of Th1 and Th2 cytokine profiles and their association with advanced head and neck squamous cell carcinoma. Otolaryngol Head Neck Surg 2004; 131: 573-576. (Pubitemid 39446277)
131. Pries R, Wollenberg B,. Cytokines in head and neck cancer. Cytokine Growth Factor Rev 2006; 17: 141-146. (Pubitemid 43949076)
132. Bergmann C, Strauss L, Wang Y, et al. T regulatory type 1 cells in squamous cell carcinoma of the head and neck: mechanisms of suppression and expansion in advanced disease. Clin Cancer Res 2008; 14: 3706-3715.
133. Chikamatsu K, Sakakura K, Whiteside TL, Furuya N,. Relationships between regulatory T cells and CD8+ effector populations in patients with squamous cell carcinoma of the head and neck. Head Neck 2007; 29: 120-127. (Pubitemid 46167778)
134. Montes CL, Chapoval AI, Nelson J, et al. Tumor-induced senescent T cells with suppressor function: a potential form of tumor immune evasion. Cancer Res 2008; 68: 870-879. (Pubitemid 351206765)
135. Bergmann C, Strauss L, Zeidler R, Lang S, Whiteside TL,. Expansion and characteristics of human T regulatory type 1 cells in co-cultures simulating tumor microenvironment. Cancer Immunol Immunother 2007; 56: 1429-1442. (Pubitemid 47024702)
136. Liss C, Fekete MJ, Hasina R, Lingen MW,. Retinoic acid modulates the ability of macrophages to participate in the induction of the angiogenic phenotype in head and neck squamous cell carcinoma. Int J Cancer 2002; 100: 283-289. (Pubitemid 34728985)
137. Liss C, Fekete MJ, Hasina R, Lam CD, Lingen MW,. Paracrine angiogenic loop between head-and-neck squamous-cell carcinomas and macrophages. Int J Cancer 2001; 93: 781-785. (Pubitemid 32756746)
138. Kanazawa T, Nishino H, Hasegawa M, et al. Interleukin-6 directly influences proliferation and invasion potential of head and neck cancer cells. Eur Arch Otorhinolaryngol 2007; 264: 815-821. (Pubitemid 46817497)
139. Grandis JR, Drenning SD, Zeng Q, et al. Constitutive activation of Stat3 signaling abrogates apoptosis in squamous cell carcinogenesis in vivo. Proc Natl Acad Sci USA 2000; 97: 4227-4232. (Pubitemid 30226115)
140. Duffy SA, Taylor JM, Terrell JE, et al. Interleukin-6 predicts recurrence and survival among head and neck cancer patients. Cancer 2008; 113: 750-757.
141. Allen C, Duffy S, Teknos T, et al. Nuclear factor-kappaB-related serum factors as longitudinal biomarkers of response and survival in advanced oropharyngeal carcinoma. Clin Cancer Res 2007; 13: 3182-31890.
142. Ritta M, De Andrea M, Mondini M, et al. Cell cycle and viral and immunologic profiles of head and neck squamous cell carcinoma as predictable variables of tumor progression. Head Neck 2009; 31: 318-327.
143. Marcus B, Arenberg D, Lee J, et al. Prognostic factors in oral cavity and oropharyngeal squamous cell carcinoma. Cancer 2004; 101: 2779-2787.
144. Mantovani A, Sozzani S, Locati M, Allavena P, Sica A,. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol 2002; 23: 549-555. (Pubitemid 35223554)
145. U'Ren L, Guth A, Kamstock D, Dow S,. Type I interferons inhibit the generation of tumor-associated macrophages. Cancer Immunol Immunother 2010; 59: 587-598.
146. Egeblad M, Nakasone ES, Werb Z,. Tumors as organs: complex tissues that interface with the entire organism. Dev Cell 2010; 18: 884-901.
147. Kaffenberger W, Clasen BP, van Beuningen D,. The respiratory burst of neutrophils, a prognostic parameter in head and neck cancer? Clin Immunol Immunopathol 1992; 64: 57-62.
148. Young MR, Wright MA, Lozano Y, et al. Increased recurrence and metastasis in patients whose primary head and neck squamous cell carcinomas secreted granulocyte-macrophage colony-stimulating factor and contained CD34+ natural suppressor cells. Int J Cancer 1997; 74: 69-74. (Pubitemid 27157858)
149. Young MR, Cigal M,. Tumor skewing of CD34+ cell differentiation from a dendritic cell pathway into endothelial cells. Cancer Immunol Immunother 2006; 55: 558-568.
150. Mulligan JK, Rosenzweig SA, Young MR,. Tumor secretion of VEGF induces endothelial cells to suppress T cell functions through the production of PGE2. J Immunother 2010; 33: 126-135.
151. Mulligan JK, Day TA, Gillespie MB, Rosenzweig SA, Young MR,. Secretion of vascular endothelial growth factor by oral squamous cell carcinoma cells skews endothelial cells to suppress T-cell functions. Hum Immunol 2009; 70: 375-382.
152. Corzo CA, Cotter MJ, Cheng P, et al. Mechanism regulating reactive oxygen species in tumor-induced myeloid-derived suppressor cells. J Immunol 2009; 182: 5693-5701.
153. Serafini P, Meckel K, Kelso M, et al. Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function. J Exp Med 2006; 203: 2691-2702. (Pubitemid 44833345)
154. Whiteside TL,. The tumor microenvironment and its role in promoting tumor growth. Oncogene 2008; 27: 5904-5912.
155. Ostrand-Rosenberg S, Sinha P,. Myeloid-derived suppressor cells: linking inflammation and cancer. J Immunol 2009; 182: 4499-4506.
156. Bronte V, Apolloni E, Cabrelle A, et al. Identification of a CD11b(+)/Gr-1(+)/CD31(+) myeloid progenitor capable of activating or suppressing CD8(+) T cells. Blood 2000; 96: 3838-3846.
157. Allen CT, Ricker JL, Chen Z, Van Waes C,. Role of activated nuclear factor-kappaB in the pathogenesis and therapy of squamous cell carcinoma of the head and neck. Head Neck 2007; 29: 959-971.
158. Allen CT, Lewis JS Jr, El-Mofty SK, Haughey BH, Nussenbaum B,. Human papillomavirus and oropharynx cancer: biology, detection and clinical implications. Laryngoscope 2010; 120: 1756-1772.
159. Pan Q, Gorin MA, Teknos TN,. Pharmacotherapy of head and neck squamous cell carcinoma. Expert Opin Pharmacother 2009; 10: 2291-2302.
160. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin 2008; 58: 71-96. (Pubitemid 351521864)
161. Crile GW Jr,., Arthur G,. Sullivan memorial lecture: factors influencing the spread of cancer. Postgrad Med 1966; 39: 331-335.
162. Morton DL,. Changing concepts of cancer surgery: surgery as immunotherapy. Am J Surg 1978; 135: 367-371. (Pubitemid 8298451)
163. Shochat S, Miller S, Snyder, P,. Evaluation of cellular immunity and adrenocortical activity in surgical patients J Surg Res 1979; 26: 332-340. (Pubitemid 9158443)
164. Shakhar G, Ben-Eliyahu S,. Potential prophylactic measures against postoperative immunosuppression: could they reduce recurrence rates in oncological patients? Ann Surg Oncol 2003; 10: 972-992. (Pubitemid 40486865)
165. Ben-Eliyahu S, Page GG, Yirmiya R, Shakhar G,. Evidence that stress and surgical interventions promote tumor development by suppressing natural killer cell activity. Int J Cancer 1999; 80: 880-888. (Pubitemid 29108864)
166. Vallejo R, Hord ED, Barna SA, Santiago-Palma J, Ahmed S,. Perioperative immunosuppression in cancer patients. J Environ Pathol Toxicol Oncol 2003; 22: 139-146. (Pubitemid 36750166)
167. Snyder GL, Greenberg S,. Effect of anaesthetic technique and other perioperative factors on cancer recurrence. Br J Anaesth 2010; 105: 106-115.
168. Carter JJ, Whelan RL,. The immunologic consequences of laparoscopy in oncology. Surg Oncol Clin N Am 2001; 10: 655-677. (Pubitemid 32881026)
169. Schuller DE,. An assessment of neck node immunoreactivity in head and neck cancer. Laryngoscope 1984; 94 (Pt 2 Suppl 35,): 1-35.
170. Forastiere AA,. Chemotherapy of head and neck cancer. Ann Oncol 1992; 3 (Suppl 3): 11-14.
171. Fairlie DP, Whitehouse MW,. Lymphoid suppression by cis-platinum(II) amines. What are the active agents? Biochem Pharmacol 1982; 31: 933-939.
172. Bose A, Ghosh D, Pal S, Mukherjee KK, Biswas J, Baral R,. Interferon alpha2b augments suppressed immune functions in tobacco-related head and neck squamous cell carcinoma patients by modulating cytokine signaling. Oral Oncol 2006; 42: 161-171. (Pubitemid 43106880)
173. Gelbard A, Garnett CT, Abrams SI, et al. Combination chemotherapy and radiation of human squamous cell carcinoma of the head and neck augments CTL-mediated lysis. Clin Cancer Res 2006; 12: 1897-1905.
174. Srikrishna G, Freeze HH,. Endogenous damage-associated molecular pattern molecules at the crossroads of inflammation and cancer. Neoplasia 2009; 11: 615-628.
175. Spanos WC, Nowicki P, Lee DW, et al. Immune response during therapy with cisplatin or radiation for human papillomavirus-related head and neck cancer. Arch Otolaryngol Head Neck Surg 2009; 135: 1137-1146.
176. Manikantan K, Khode S, Sayed SI, et al. Dysphagia in head and neck cancer. Cancer Treat Rev 2009; 35: 724-732.
177. Gough MJ, Crittenden MR,. Combination approaches to immunotherapy: the radiotherapy example. Immunotherapy 2009; 1: 1025-1037.
178. Bogdandi EN, Balogh A, Felgyinszki N, et al. Effects of low-dose radiation on the immune system of mice after total-body irradiation. Radiat Res 2010; 174: 480-489.
179. Ganem G, Cartron G, Girinsky T, Haas RL, Cosset JM, Solal-Celigny P,. Localized low-dose radiotherapy for follicular lymphoma: history, clinical results, mechanisms of action, and future outlooks. Int J Radiat Oncol Biol Phys 2010; 78: 975-982.
180. Jenkins VK, Griffiths CM, Ray P, Perry RR, Olson MH,. Radiotherapy and head and neck cancer. Role of lymphocyte respontse and clinical stage. Arch Otolaryngol 1980; 106: 414-418. (Pubitemid 10071624)
181. Nordman E, Toivanen A,. Effects of irradiation on the immune function in patients with mammary, pulmonary or head and neck carcinoma. Acta Radiol Oncol Radiat Phys Biol 1978; 17: 3-9. (Pubitemid 9068787)
182. Stefani SS, Kerman RH,. Lymphocyte response to phytohaemagglutinin before and after radiation therapy in patients with carcinomas of the head and neck. J Laryngol Otol 1977; 91: 605-609. (Pubitemid 8135852)
183. Wara WM, Phillips TL, Wara DW, Ammann AJ, Smith V,. Immunosuppression following radiation therapy for carcinoma of the nasopharynx. Am J Roentgenol Radium Ther Nucl Med 1975; 123: 482-485.
184. Garnett CT, Palena C, Chakraborty M, Tsang KY, Schlom J, Hodge JW,. Sublethal irradiation of human tumor cells modulates phenotype resulting in enhanced killing by cytotoxic T lymphocytes. Cancer Res 2004; 64: 7985-7994. (Pubitemid 39446933)
185. O'Malley BW Jr, Li D, McQuone SJ, Ralston R,. Combination nonviral interleukin-2 gene immunotherapy for head and neck cancer: from bench top to bedside. Laryngoscope 2005; 115: 391-404. (Pubitemid 40327983)
186. De Stefani A, Forni G, Ragona R, et al. Improved survival with perilymphatic interleukin 2 in patients with resectable squamous cell carcinoma of the oral cavity and oropharynx. Cancer 2002; 95: 90-97. (Pubitemid 34743486)
187. Richtsmeier WJ, Koch WM, McGuire WP, Poole ME, Chang EH,. Phase I-II study of advanced head and neck squamous cell carcinoma patients treated with recombinant human interferon gamma. Arch Otolaryngol Head Neck Surg 1990; 116: 1271-1277. (Pubitemid 20362054)
188. Seixas-Silva JA Jr, Richards T, Khuri FR, et al. Phase 2 bioadjuvant study of interferon alfa-2a, isotretinoin, and vitamin E in locally advanced squamous cell carcinoma of the head and neck: long-term follow-up. Arch Otolaryngol Head Neck Surg 2005; 131: 304-307. (Pubitemid 40517029)
189. Urba SG, Forastiere AA, Wolf GT, Amrein PC,. Intensive recombinant interleukin-2 and alpha-interferon therapy in patients with advanced head and neck squamous carcinoma. Cancer 1993; 71: 2326-2331. (Pubitemid 23087775)
190. van Herpen CM, Looman M, Zonneveld M, et al. Intratumoral administration of recombinant human interleukin 12 in head and neck squamous cell carcinoma patients elicits a T-helper 1 profile in the locoregional lymph nodes. Clin Cancer Res 2004; 10: 2626-2635. (Pubitemid 38509135)
191. Rapidis AD, Wolf GT,. Immunotherapy of head and neck cancer: current and future considerations. J Oncol 2009; 2009: 346345.
192. Meneses A, Verastegui E, Barrera JL, Zinser J, de la Garza J, Hadden JW,. Histologic findings in patients with head and neck squamous cell carcinoma receiving perilymphatic natural cytokine mixture (IRX-2) prior to surgery. Arch Pathol Lab Med 1998; 122: 447-454. (Pubitemid 28237539)
193. Meneses A, Verastegui E, Barrera JL, de la Garza J, Hadden JW,. Lymph node histology in head and neck cancer: impact of immunotherapy with IRX-2. Int Immunopharmacol 2003; 3: 1083-1091. (Pubitemid 36830853)
194. Egan JE, Quadrini KJ, Santiago-Schwarz F, Hadden JW, Brandwein HJ, Signorelli KL,. IRX-2, a novel in vivo immunotherapeutic, induces maturation and activation of human dendritic cells in vitro. J Immunother 2007; 30: 624-633. (Pubitemid 47229697)
195. Czystowska M, Han J, Szczepanski MJ, et al. IRX-2, a novel immunotherapeutic, protects human T cells from tumor-induced cell death. Cell Death Differ 2009; 16: 708-718.
196. Naylor PH, Hernandez KE, Nixon AE, et al. IRX-2 increases the T cell-specific immune response to protein/peptide vaccines. Vaccine 2010; 28: 7054-7062.
197. Hadden J, Verastegui E, Barrera JL, et al. A trial of IRX-2 in patients with squamous cell carcinomas of the head and neck. Int Immunopharmacol 2003; 3: 1073-1081. (Pubitemid 36830852)
198. Sharafinski ME, Ferris RL, Ferrone S, Grandis JR,. Epidermal growth factor receptor targeted therapy of squamous cell carcinoma of the head and neck. Head Neck 2010; 32: 1412-1421.
199. Ferris RL, Jaffee EM, Ferrone S,. Tumor antigen-targeted, monoclonal antibody-based immunotherapy: clinical response, cellular immunity, and immunoescape. J Clin Oncol 2010; 28: 4390-4399.
200. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006; 354: 567-578. (Pubitemid 43209104)
201. Burtness B,. The role of cetuximab in the treatment of squamous cell cancer of the head and neck. Expert Opin Biol Ther 2005; 5: 1085-1093. (Pubitemid 41170037)
202. Chung KY, Shia J, Kemeny NE, et al. Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J Clin Oncol 2005; 23: 1803-1810. (Pubitemid 46211358)
203. Klinghammer K, Knodler M, Schmittel A, Budach V, Keilholz U, Tinhofer I,. Association of epidermal growth factor receptor polymorphism, skin toxicity, and outcome in patients with squamous cell carcinoma of the head and neck receiving cetuximab-docetaxel treatment. Clin Cancer Res 2010; 16: 304-310.
204. Lopez-Albaitero A, Ferris RL,. Immune activation by epidermal growth factor receptor specific monoclonal antibody therapy for head and neck cancer. Arch Otolaryngol Head Neck Surg 2007; 133: 1277-1281. (Pubitemid 350294259)
205. Kurai J, Chikumi H, Hashimoto K, et al. Antibody-dependent cellular cytotoxicity mediated by cetuximab against lung cancer cell lines. Clin Cancer Res 2007; 13: 1552-1561. (Pubitemid 46450447)
206. Taylor RJ, Chan SL, Wood A, et al. FcgammaRIIIa polymorphisms and cetuximab induced cytotoxicity in squamous cell carcinoma of the head and neck. Cancer Immunol Immunother 2009; 58: 997-1006.
207. Fujita K, Sano D, Kimura M, et al. Anti-tumor effects of bevacizumab in combination with paclitaxel on head and neck squamous cell carcinoma. Oncol Rep 2007; 18: 47-51.
208. Hu JC, Coffin RS, Davis CJ, et al. A phase I study of OncoVEXGM-CSF, a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colony-stimulating factor. Clin Cancer Res 2006; 12: 6737-6747. (Pubitemid 44876843)
209. Harrington KJ, Hingorani M, Tanay MA, et al. Phase I/II study of oncolytic HSV GM-CSF in combination with radiotherapy and cisplatin in untreated stage III/IV squamous cell cancer of the head and neck. Clin Cancer Res 2010; 16: 4005-4015.
210. Devaraj K, Gillison ML, Wu TC,. Development of HPV vaccines for HPV-associated head and neck squamous cell carcinoma. Crit Rev Oral Biol Med 2003; 14: 345-362. (Pubitemid 44560789)
211. Zhang X, Moche JA, Farber D, Strome SE,. Vaccine-based approaches to squamous cell carcinoma of the head and neck. Oral Dis 2007; 13: 17-22. (Pubitemid 46046530)
212. Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010; 363: 411-422.
213. Chang AE, Li Q, Jiang G, Teknos TN, Chepeha DB, Bradford CR,. Generation of vaccine-primed lymphocytes for the treatment of head and neck cancer. Head Neck 2003; 25: 198-209. (Pubitemid 36245878)
214. To WC, Wood BG, Krauss JC, et al. Systemic adoptive T-cell immunotherapy in recurrent and metastatic carcinoma of the head and neck: a phase 1 study. Arch Otolaryngol Head Neck Surg 2000; 126: 1225-1231.
215. Yang BB, Jiang H, Chen J, Zhang X, Ye JJ, Cao J,. Dendritic cells pulsed with GST-EGFR fusion protein: effect in antitumor immunity against head and neck squamous cell carcinoma. Head Neck 2010; 32: 626-635.
216. Lu J, Higashimoto Y, Appella E, Celis E,. Multiepitope Trojan antigen peptide vaccines for the induction of antitumor CTL and Th immune responses. J Immunol 2004; 172: 4575-4582. (Pubitemid 38375275)
217. Badoual C, Sandoval F, Pere H, et al. Better understanding tumor-host interaction in head and neck cancer to improve the design and development of immunotherapeutic strategies. Head Neck 2010; 32: 946-958.
218. Sano D, Myers JN,. Xenograft models of head and neck cancers. Head Neck Oncol 2009; 1: 32.
219. Disis ML,. Immune regulation of cancer. J Clin Oncol 2010; 28: 4531-4538.
220. Stanley M,. HPV: immune response to infection and vaccination. Infect Agent Cancer 2010; 5: 19.
221. Prince ME, Sivanandan R, Kaczorowski A, et al. Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma. Proc Natl Acad Sci USA 2007; 104: 973-978. (Pubitemid 46154721)
222. Clay MR, Tabor M, Owen JH, et al. Single-marker identification of head and neck squamous cell carcinoma cancer stem cells with aldehyde dehydrogenase. Head Neck 2010; 32: 1195-1201.
223. Reya T, Morrison SJ, Clarke MF, Weissman IL,. Stem cells, cancer, and cancer stem cells. Nature 2001; 414: 105-111. (Pubitemid 33041634)
224. Hirohashi Y, Torigoe T, Inoda S, et al. Immune response against tumor antigens expressed on human cancer stem-like cells/tumor-initiating cells. Immunotherapy 2010; 2: 201-211.